Breakthrough in Japan-India trade talks, including pharma, look set to see signing of FTA this year

12 April 2010

After three days of talks last week, officials from India and Japan have resolved several stumbling blocks to their proposed free trade agreement (FTA) - opening up sectors like pharmaceuticals and services ' and thus raising prospects for its signing during the current year.

Once the FTA, officially dubbed as the Comprehensive Economic Partnership Agreement (CEPA), is signed and put into operation, as many 9,000 products - ranging from steel and apparel to drugs and machinery - are expected to be traded either without duty or at substantially reduced tariffs, reports the Economic Times of India. "The next round of talks would be held at a senior level," a source told the newspaper.

The FTA would keep a number of items, sensitive to the agriculture and employment-oriented sectors, out of the purview of both countries. Each side will have its own negative list of items. However, India's list would be bigger, with 8%of the tradeable items included. It will be 3% for Japan, sources said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics